ACADIA PHARMACEUTICALS INC (ACAD) Stock News
NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD
ACAD Latest News, Press Relases and Analysis
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FENC
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.
Analysts Estimate Fortrea Holdings Inc. (FTRE) to Report a Decline in Earnings: What to Look Out for
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: FTRE
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: YMAB
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.